Apolipoprotein E Reduces Tau Kinases and Phosphorylated Tau Levels in Neurons
Author Information
Author(s): Hoe Hyang-Sook, Freeman Jacob, Rebeck G William
Primary Institution: Georgetown University
Hypothesis
Does apoE treatment of neurons affect the phosphorylation of tau and its associated kinases?
Conclusion
ApoE treatment decreases tau kinases and phosphorylated tau levels in primary neurons, potentially influencing tau pathology in Alzheimer's disease.
Supporting Evidence
- ApoE treatment significantly decreased levels of phosphorylated GSK 3β, P35, and CDK5.
- ApoE peptide treatment resulted in a 70-90% decrease in phospho-tau proteins.
- Treatment with 2 uM apoE increased levels of unphosphorylated tau by 115%.
- Effects of apoE on tau phosphorylation were blocked by an inhibitor of LDL receptors.
Takeaway
Apolipoprotein E helps keep a protein called tau from getting too sticky in brain cells, which is important for preventing Alzheimer's disease.
Methodology
Primary neurons were treated with apoE and analyzed for levels of tau kinases and phosphorylated tau using immunoblotting.
Limitations
The study primarily focuses on in vitro results, which may not fully represent in vivo conditions.
Participant Demographics
Primary mouse embryonic cortical neurons from E16 Swiss-Webster mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website